miR-200b is involved in intestinal fibrosis of Crohn's disease

YINGWEI CHEN1-3, WENSONG GE1, LEIMING XU1, CHUNYING QU1, MINGJIE ZHU1, WENZHU ZHANG3 and YONGTAO XIAO1,2

1Department of Gastroenterology, Shanghai Jiao Tong University, School of Medicine, Xin Hua Hospital, Shanghai; 2Shanghai Institute of Pediatric Research, Shanghai; 3Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai; 4Department of Pathology, Shanghai Jiao Tong University, School of Medicine, Xin Hua Hospital, Shanghai, P.R. China

Received November 12, 2011; Accepted December 23, 2011

DOI: 10.3892/ijmm.2012.894

Abstract. Intestinal fibrosis is one of the major serious complications of Crohn's disease (CD). However, there are no effective antifibrotic drugs to treat intestinal fibrosis in CD. Therefore, it is important to understand the pathogenesis of fibrosis in CD. It has been reported that members of the miR-200 family are essential in the regulation of renal fibrogenesis. In this study, we analyzed the function of miR-200a and miR-200b in intestinal fibrosis, which was induced by transforming growth factor β1 (TGF-β1) in vitro. Furthermore, we detected the expression of miR-200a and miR-200b in CD specimens, which were divided into groups of fibrosis and no-fibrosis. The results of this study showed that administration of miR-200b could partially protect intestinal epithelial cells from fibrogenesis in vitro. Furthermore, we found that miR-200b was overexpressed in the serum of the fibrosis group. The results suggest that miR-200b has potential value for diagnostic and therapeutic applications for CD patients with fibrosis complications.

Introduction

Fibrosis is one of major complications in Crohn's disease (CD), which results from chronic inflammation. Severe fibrosis could result in critical narrowing of the lumen stenosis, or stricture, commonly leading to obstruction that requires surgical or mechanical intervention (1-3). At present, there are no approved or effective medical therapies aimed specifically at fibrosis or stricture in CD. Anti-inflammatory therapies do not prevent fibrosis nor do they reverse established strictures, which may present years after remission of active inflammation. Although this study is still limited, it can expand our understanding of cellular and molecular mechanisms leading to fibrosis in CD.

microRNAs (miRNAs) are noncoding RNAs that negatively regulate target genes expression at the post-transcriptional level. There is growing evidence to suggest that members of miR-200 family are implicated in diverse biological and pathological processes. Recent ground-breaking studies have established functional associations between miR-200 and key effectors of the epithelial-to-mesenchymal-transition (EMT) occurring in the context of carcinogenesis and embryonic development. Gregory et al (4) reported that miR-200 and miR-205 could inhibit the zinc finger E-box-binding homeobox 1 (ZEB1) and ZEB2, ZEB1 (TCF8/EF1) and ZEB2 [SMAD-interacting protein 1 (SIP1)/ZFXH1B] and thus maintain the epithelial cell phenotype (4). Oba et al (5) indicated that a miR-200b precursor could ameliorate renal tubulointerstitial fibrosis. The purpose of this study was to investigate the role of miR-200a and miR-200b in the pathogenesis of intestinal fibrosis. Initial experiments demonstrated that introduction of miR-200b in intestinal epithelial cells could partially oppose fibrosis, which was induced by transforming growth factor β1 (TGF-β1). Subsequent data showed the aberrant expression of miR-200b in serum is a potential diagnostic marker for CD patients with fibrosis complications.

Materials and methods

TGF-β1-induced fibrosis in vitro. DLD-1 was a colorectal adenocarcinoma epithelial cell line, which was cultured in DMEM (Gibco) containing 10% fetal bovine serum (FBS). DLD-1 cells were stimulated with 10 ng/ml (TGF-β1, Sigma) for 24, 48 and 72 h. The total RNA and protein were harvested at the above-indicated times. To investigate the effect of miRNAs on fibrosis, DLD-1 cells were transfected with 50 pM miR-200a or miR-200b for 24 h using Lipofectamine RNAiMAX (Invitrogen), then stimulated with 10 ng/ml TGF-β1. After 24 h, the cells were harvested by extracting total-RNA and protein.

miRNA assays. Total-RNA was extracted from serum, tissues of patients and DLD-1 cells by using the mirVana PARIS and mirVana miRNA isolation kit (Ambion). TaqMan miRNA assay (Applied Biosystems) was used to quantify the relative expression level of miR-200a (assay ID. 000502), miR-200b (assay ID. 002251), and U6 (assay ID. 001093) was used as
CHEN et al: miR-200b AND FIBROSIS OF CROHN’S DISEASE PATIENTS

Table I. Characteristics of Crohn’s disease patients.

| Age | Gender | Diagnosis | Tissue-staining | N-cadherin staining | Vimentin staining | α-SMA |
|-----|--------|-----------|-----------------|---------------------|-------------------|-------|
|     |        |           | Intestine/serum |         | +     |       |
|     |        |           | Intestine/serum | ++     | +     | +     |
|     |        |           | Intestine, colon/serum | ++     | +     | +     |
|     |        |           | Intestine, colon/serum | +++    | +     | +     |
|     |        |           | Intestine, sigmoid/serum | +++    | +     | +     |
|     |        |           | Intestine, sigmoid/serum | +++    | +     | +     |

No-fibrosis

| Age | Gender | Diagnosis | Tissue-staining | N-cadherin staining | Vimentin staining | α-SMA |
|-----|--------|-----------|-----------------|---------------------|-------------------|-------|
|     |        | Colon ascendens, intestine/serum | -     | +     | -     |
|     |        | Intestine/serum | +     | -     | -     |
|     |        | Intestine, colon/serum | -     | -     | -     |
|     |        | Intestine, sigmoid/serum | -     | -     | -     |
|     |        | Intestine, sigmoid/serum | -     | -     | -     |
|     |        | Intestine/serum | -     | -     | -     |

Crohn’s disease patients were divided into two subgroups, fibrosis and no fibrosis, according to the staining of α-smooth muscle actin (α-SMA) and vimentin, which are the two markers of fibrosis. (+, mild; ++, moderate; ++++, strong).

an internal control. cDNA was synthesized using the TaqMan miRNA Reverse Transcription kit (Applied Biosystems). The reaction was performed for 30 min at 16°C, 30 min at 42°C, and 5 min at 85°C. The LightCycler® 480 Real-Time PCR System (Roche) was used to detect miRNA expression. All reactions were run in triplicate.

Real-time PCR. The total-RNA was extracted from DLD-1 cells with TRIZol (Invitrogen) according to the protocol of manufacture. Real-time PCR was performed to measure the expression of vimentin, fibronectin, E-cadherin, fibronectin. Real-time PCR was performed with the following PCR primers: GAPDH, forward, 5′-GAAGGTGAAGGTCGGAGTC-3′ and reverse, 5′-GAAGATGGTGATGGGATTTC-3′; CDH1, forward, 5′-GGAGGAGAGCGGTGGTCAAA-3′ and reverse, 5′-TGTGCCAGCTGGCTCAAGTCAA-3′; vimentin, forward, 5′-CCTGCAGGAGCTTT-3′ and reverse, 5′-CTGCCAGGTGTT-3′; α-SMA, forward, 5′-CCGACCGAATGCAAA-3′ and reverse, 5′-ACAGAGTATTTGCGCTCAGA-3′; fibronectin, forward, 5′-AGACCATACCTGCCGAATG-3′ and reverse, 5′-CCCTATGGGCATTATTTGAG-3′; SYBR-Green Universal Master Mix kit (ABI) and High Capacity cDNA Reverse Transcription kit (ABI) were employed to detect the levels of these genes. All reactions were repeated four times and GAPDH was used to normalize the target genes.

Western blotting. Protein of 20 µg/well was separated on 4-12% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Invitrogen) using a dry blotting system (Invitrogen). After blocking in 1X TBST, 5% nonfat dry milk, 0.2% Tween-20 at room temperature for 30 min. The membranes were incubated with the primary antibodies in blocking buffer (1X TBST, 5% nonfat dry milk, 0.2% Tween-20) overnight at 4°C. Antibodies were used at a dilution of 1:1,000. The membranes were washed three times for 30 min with 1X TBST and then incubated with secondary antibodies at a final dilution of 1:2,000. After final washes with 1X TBS, 0.2% Tween-20, the signals were detected using ECL chemiluminescence reagents (Pierce). Antibodies of N-cadherin, E-cadherin, vimentin and actin α2 smooth muscle (α-SMA) were used in this assay. To confirm that the same amount of protein was investigated, the expression of GAPDH was investigated simultaneously.

Specimen preparation. A total of 20 tissue specimens from CD patients (10 fibrosis samples and 10 no-fibrosis samples) were obtained from the Department of Pathology, Xinhua Hospital, Shanghai, China. The blood samples were donated from the above patients (Table I). All of the patients or their guardians provided written informed consent, and Faculty of Medicine’s Ethics Committee of Xinhua Hospital approved all aspects of this study.

Immunohistochemistry. Immunohistochemical studies for the expression of N-cadherin, E-cadherin, vimentin, and α-SMA were performed on 20 CD samples by using an avidin-biotin peroxidase method with diaminobenzidine (DAB) chromogen.
After antigen retrieval (microwave treatment of formalin-fixed, paraffin-embedded, 40 min at 240 W in citrate buffer, pH 6.0), the tissues were blocked with bovine serum albumin (BSA). As primary antibodies, mouse monoclonal and rabbit polyclonal antibodies (N-cadherin, Novus, dilution 1:200; E-cadherin, Cell Signal Technology, dilution 1:200; vimentin, Cell Signal Technology, 1:100; α-SMA, Novus, dilution 1:200) were used in this study. After incubation for 30 min at 37˚C the slides were rinsed in phosphate-buffered saline (PBS) and incubated with the secondary antibody for 2 h at room temperature. Antibody binding was visualized with 0.05% DAB and 0.01% hydrogen peroxide. The material was rinsed in PBS and counterstained with hematoxylin.

Statistical analysis. All data are presented as mean ± SD. When comparisons were made between two different groups, statistical significance was determined by the Student’s t-test using the StatView software program.

Results

Established TGF-β1-induces fibrosis in vitro. It is well accepted that TGF-β is a major inducer of fibrosis and has different isoforms. High levels of TGF-β1 have often been found in many fibrotic tissues, and have been implicated as a mediator of fibrosis in many diseases. Furthermore, TGF-β1 was firstly identified as an inducer of EMT in normal mammary epithelial cells and has since been shown to mediate EMT in a number of different epithelial cells, including renal proximal tubular and lens cells (6-9). Here, in order to clarify the effect of miR-200a and miR-200b on intestinal fibrosis, we initially established a TGF-β1-induced fibrotic model in vitro in a colorectal epithelial cell line (DLD-1). In this model, the DLD-1 cells were stimulated with TGF-β1 (10 ng/ml) for 24, 48, and 72 h. Real-time PCR and western blot analysis demonstrated that TGF-β1 mediated repression of E-cadherin, and induction of N-cadherin, α-SMA, fibronectin, and vimentin. E-cadherin was known to be involved in homophilic interactions between epithelial cells and was necessary for the formation of zonulae occludens. In the normal intestinal epithelial cells, E-cadherin staining was strong at the lateral cell membrane between cell contact areas (10). However, E-cadherin expression was lost or was significantly reduced during the process of EMT. N-cadherin, which is usually expressed in mesenchymal cells and fibroblasts, has often been used to monitor the progress of EMT and fibrogenesis (11,12). Vimentin is a type III intermediate filament protein that is expressed in mesenchymal cells and fibroblasts (13,14). During the development of intestinal fibrosis in responding to chronic pressure or volume overload, fibroblasts could become activated to become myofibroblasts, which strongly express α-SMA and secrete abundant, disorganized collagen (15-17). The above data indicate that TGF-β1 not only induced fibrosis, but also the EMT process. At the same time, we found that the expression of miR-200a and miR-200b were significantly inhibited by TGF-β1 (Fig. 1).

miR-200b ameliorates TGF-β1-induced fibrosis. We next investigated the role of miR-200a and miR-200b in intestinal fibrogenesis in vitro, with TGF-β1 stimulated DLD-1 cells for 24 h prior to introduction of miR-200a or miR-200b. miR-200b, but not miR-200a, increased the expression of E-cadherin and simultaneously reduced the expression of vimentin, fibronectin and N-cadherin (Fig. 2). It was thus suggested that miR-200b could ameliorate the fibrosis or EMT of intestinal...
CHEN et al: miR-200b AND FIBROSIS OF CROHN’S DISEASE PATIENTS

Recent studies have indicated that the transcriptional repressors ZEB1 (TCF8/EF1) and ZEB2 [SMAD-interacting protein 1 (SIP1)/ZFXH1B] are two direct targets of members of the miR-200 family (4). Here, real time PCR analysis showed that ZEB1 and ZEB2 were significantly inhibited by miR-200a or miR-200b (Fig. 2). These results support the notion that miR-200b could ameliorate intestinal fibrosis through downregulation of ZEB1, ZEB2.

miR-200 is related to fibrogenesis of CD. Intestinal fibrosis is a major complication of CD, but the precise mechanism is only partially understood. As a result, the exploration of specific therapies to halt fibrosis have been hindered. Here, we evaluated the possible contribution of the epithelial to mesenchymal transition (EMT) to intestinal fibrosis associated with CD. We detected the expression of specific markers of EMT and fibrosis in twenty CD specimens (10 fibrosis, and 10 no-fibrosis) by immunohistochemistry. Compared to the no-fibrosis specimens, we found that staining of N-cadherin, α-SMA and vimentin was very strong in fibrosis specimens (Fig. 3, Table I). These results prompted us to assess whether miR-200a or miR-200b are related to fibrogenesis of CD.

 Serum miR-200b is a potential diagnostic marker for CD with fibrosis complications. In previous studies, Murakami et al (18) showed that overexpression of miR-200b could be connected to the progression of liver fibrosis. In order to investigate whether miR-200a or miR-200b could serve as diagnostic markers for CD fibrosis, we evaluated their expression in CD serum. We collected 10 fibrosis and 10 no-fibrosis blood samples and calculated the expression of miR-200a and miR-200b by TaqMan real-time PCR. Sixteen healthy blood samples were used as negative control. The results indicate
that miR-200b increased significantly in serum of the fibrosis group when compared to that of the no-fibrosis group or from healthy individuals, (P<0.05, P<0.01). For miR-200a, we could not find a significant difference between the fibrosis and no-fibrosis groups (P>0.05) (Fig. 4).

Discussion

Intestinal fibrosis is a common complication of CD that may require surgical intervention if it became seriously symptomatic. The traditional mechanisms underlying intestinal fibrosis are associated to the presence of chronic inflammation. However, it is also possible that novel mechanisms independent of persistent immune activation exist in the gut (18,19). At present, the development of a preventive and more effective management of intestinal fibrosis is hampered by the lack of a in-depth understanding of the basic pathophysiological factors involved in it. To provide novel mechanisms for intestinal fibrosis, we revealed the association between miR-200 and intestinal fibrosis. Initially, we analyzed the role of miR-200a and miR-200b in the intestinal fibrosis in vitro. The findings indicate that miR-200b could ameliorate intestinal fibrosis that was induced by TGF-β1. Several studies have shown that the members of the miR-200 family could target ZEB1 and ZEB2 (4) directly. Here, we indicated that ZEB1 and ZEB2 decreased significantly in the presence of miR-200a or miR-200b. It was suggested that miR-200b inhibited the process of intestinal fibrosis through repressing ZEB1 and ZEB2. However, more studies are needed to investigate the exact mechanisms involved (Figs. 1 and 2).

To provide further evidence for intestinal fibrosis, we revealed the association between miR-200 expression and CD fibrosis. We divided CD samples into two groups: fibrosis and no-fibrosis. Then, we evaluated the expression of miR-200a and miR-200b in the serum of CD samples. The results showed that miR-200b was significantly elevated in the group of CD fibrosis compared to the no-fibrosis group or the healthy controls, but surprisingly, miR-200a did not increase (Fig. 4). miRNAs are usually described as highly tissue-specific biomarkers with potential clinical applicability for defining the cancer origin of metastases. Recent studies suggested that circulating miRNA has been a valuable biomarker for several diseases, including different types of cancer (20-39). In this study, it was shown that expression of miR-200b increased significantly in the serum of the CD fibrosis group. This led us to hypothesize that serum miR-200b could be a candidate CD fibrosis diagnostic biomarker.

EMT is a process in which epithelial cells lose their phenotypic and functional characteristics while acquiring mesenchymal features. Although EMT is not a common event in adults, this process has been implicated in such instances as wound healing and fibrosis. The role of EMT in intestinal fibrosis has yet to be investigated. Intestinal fibrosis is thought to occur as a result of chronic inflammation and dysregulated wound healing (40,41). In this study, we demonstrated that EMT may promote intestinal fibrogenesis, which was probably inhibited by miR-200b (Figs. 3 and 5). In future studies, we will attempt to provide additional evidence to prove this hypothesis.

Acknowledgements

This study was supported by the Key Scientific Research Program of the Shanghai Health Bureau (20100005), Program for Innovative Research Team of the Shanghai Municipal Education Commission and by funding of the Xinhua Hospital (11QYJ010) and Shanghai Key Laboratory of Pediatric Gastroenterology.
and Nutrition (11DZ2260500). We thank Professor W. Cai for his contribution.

References

1. Pucilowska JB, Williams KL and Lund PK: Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 279: G653-G659, 2000.

2. Rieder F and Fiocchi C: Intestinal fibrosis in inflammatory bowel disease - current knowledge and future perspectives. J Crohns Colitis 2: 279-290, 2008.

3. Rieder F and Fiocchi C: Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol 24: 462-468, 2008.

4. Gregory PA, Bert AG, Paterson EL, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601, 2008.

5. Oba S, Kumano S, Suzuki E, et al: Oligo-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One 5: e13614, 2010.

6. Lamouille S and Derynck R: Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178: 437-451, 2007.

7. Hill JJ, Tremblay LT, Cantin C, O'Connor-McCourt M, Kelly JF and Lenferink AE: Glycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-beta induced epithelial to mesenchymal transition. Proteome Sci 7: 2, 2009.

8. Roberts AB, Tian F, Byfield SD, et al: Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 17: 19-27, 2006.

9. Xu J, Lamouille S and Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.

10. Gravdal K, Halvorsen OJ, Afdhal NH and Albitar M: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 102: 735-741, 2010.

11. Nakajima S, Doi R, Toyoda E, et al: N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 10: 4125-4133, 2004.

12. Kim JB, Islam S, Kim YJ, et al: N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. J Cell Biol 151: 1193-1206, 2000.

13. Vuoriluoto K, Haugen H, Kiviluoto S, et al: Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30: 1436-1448, 2011.

14. Iwasaki J: Vimentin: central hub in EMT induction? Small Gtpases 2: 51-53, 2011.

15. Carpino G, Morini S, Ginianni Corradini S, et al: Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis 37: 349-356, 2005.

16. Ina K, Kitamura H, Tatsukawa S and Fujikura Y: Significance of alpha-sma in myofibroblasts emerging in renal tubulointerstitial fibrosis. Histol Histopathol 26: 855-866, 2011.

17. Akpolat N, Yalhis S, Godekmerdan A, Yalniz M and Demirkap B: The role of alpha-SMA in the evaluation of hepatic fibrosis severity in hepatitis B infection and cirrhosis development: a histopathological and immunohistochemical study. Histopathology 47: 276-280, 2005.

18. Murakami Y, Toyoda H, Tanaka M, et al: The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 6; e16081, 2011.

19. Van Moerkerken W, Debever G, Lambrecht G and Hetveldt K: Severe bridging fibrosis of the colon in a man with inflammatory bowel disease. Endoscopy 39 (Suppl 1): E294, 2007.

20. Ai J, Zhang R, Li Y, et al: Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 391: 73-77, 2010.

21. Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087-2092, 2010.

22. Zahm AM, Thauy M, Hand NJ, Horner A, Leonard MB and Friedman JR: Circulating microRNA is a biomarker of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 53: 23-33, 2011.

23. Wang G, Zhu JQ, Zhang JT, et al: Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31: 659-666, 2010.

24. Mahr H, Reukamp LC, Rogenhofer S, von Rucker A, Muller SC and Ellinger J: Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77: 1263-1266, 2011.

25. D’Alessandra Y, Devanna P, Limana F, et al: Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 31: 2765-2773, 2010.

26. Gupta SK, Bang C and Thum T: Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet 3: 484-488, 2010.

27. Qu KZ, Zhang K, Li H, Afdhal NH and Albitar M: Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 45: 355-360, 2011.

28. Roth C, Rack B, Muller V, Jann W, Pantel K and Schwarzenbach H: Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 12: R90, 2010.

29. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251: 499-505, 2010.

30. Contu R, Latronico MV and Condorelli G: Circulating microRNAs as potential biomarkers of coronary artery disease: a promise to be fulfilled? Circ Res 107: 573-574, 2010.

31. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.

32. Zhu W, Qin W, Atasoy U and Sauter ER: Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2: 89, 2009.

33. Fichtlischer S, De Rosa S, Fox H, et al: Circulating microRNAs in patients with coronary artery disease. Circ Res 107: 677-684, 2010.

34. Tsujiura M, Ichikawa D, Komatsu S, et al: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 102: 1174-1179, 2010.

35. Komatsu S, Ichikawa D, Takeda H, et al: Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 105: 104-111, 2011.

36. Zuo Z, Calin GA, de Paula HM, et al: Circulating microRNAs in patients with prostate cancer. Urology 77: 1265-1266, 2011.

37. Wang K, Zhang S, Marzolf B, et al: Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 106: 4402-4407, 2009.

38. Lopez-Novoa JM and Nieto MA: Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 1: 303-314, 2009.

39. Lund PK and Zuniga CC: Intestinal fibrosis in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 17: 318-323, 2001.